Erratum

Ramirez E, Laosa O, Guerra P, Duque B, Mosquera B, Borobia AM, Lei SH, Carcas AJ, Frias J. Br J Clin Pharmacol 2010; 70: 694–702.

In [1], the article states that loratadine is a BCS Class I drug (in Table 1, column 1, line 10; Table 4, column 1, line 14; and page 698, column 1, line 4). Data were obtained from the Therapeutic System Research Laboratories website (at http://www.tsrlinc.com/services/bcs/search.cfm). The new website of Therapeutic System Research Laboratories at http://69.20.123.154/services/bcs/results.cfm yields a page displaying loratadine as Class II and the metabolite desloratadine as Class I (last accessed March 21, 2012).

Table 1.

Biopharmaceutics Classification System (BCS) of active substances (number of studies)

Table 4.

Results of non-BE formulations (study number of subjects, retrospective sample size calculation) classified by BCS active substances for maximum observed plasma concentration (C_max) and area under the concentration-time curve (AUC)

The corrected versions of Table 1 and 4 and the sentence on page 698 are published below.

In one case (sildenafil) the CV_Intrasubject was higher than predicted (Group A2 Table 4).